Genes & Diseases

基因与疾病（英文）

Volume 10 Issue 1
January 2023

eISSN 2352-3042
pISSN 2352-4820
CN 50-1221/R

an international journal for molecular and translational medicine

Highlights

Core Promoter Variation in Triple-negative Breast Cancer
Targeting RAS-RAF-MEK-ERK Axis in Cancer Therapies
Paradoxical Relationship between Inflammation and Cancer



KeAi

Genes & Diseases

CONTENTS

Volume 10, Issue 1 **January 2023**

RESEARCH HIGHLIGHTS

1 Phase 'separating' 53BP1 from DSB repair
Y. Zhang

4 Metagenomic markings of myeloid malignancies
A. D. D. Nguyen, M. Shanteau-Jackson and T. LaFramboise

7 Does burning fat make tumor immune hot? Discovery of CD47 overexpression by radiation induced fatty acid oxidation
N. Jiang, B. Xie, M. Fan and J. J. Li

RNA polymerase II (Pol II) core promoter usually locates around the transcriptional start site with multiple highly conserved cis-elements. Core promoter sequences can be bound by Pol II and basal transcriptional factors (TFs) (i.e., TFIIA, TFIIB, TFIIC, TFIID, TFIIE and TFIIH), which form the pre-initiation complex (PIC) and then initiate the downstream genes expression. Abnormal gene expression plays a key role in cancer development. Huang et al reported the core promoter sequences are highly mutable in cancer. The mutated core promoter sequences can interfere with their interactions with transcriptional factors, resulting in altered transcriptional initiation and abnormal gene expression in triple-negative breast cancer (TNBC). Fortunately, some drugs targeting such core promoter variations have been found and may have potential clinical applications. As inspired by the legendary Chinese female fighter "Hua Mulan", who excelled in battlefields even more bravely than men. To protect her from being knocked over by an adversary (i.e., core promoter variation and abnormal gene expression in TNBC), precision targeting with spurred armors (i.e., targeted therapies of TNBC) is highly warranted (Illustration credit: Huijie Zhang, PhD, and Zijian Qu).

RAPID COMMUNICATIONS

10 Nuclear lncRNA CERNA1 enhances the cisplatin-induced cell apoptosis and overcomes chemoresistance via epigenetic activation of BCL2L10 in ovarian cancer
R. Xu, H. Peng, N. Yang, Z. Liu and W. Lu

14 PTGS2 identified as a biomarker of glucocorticoid-induced osteonecrosis of the femoral head and an enhancer of osteogenesis
Q. Zhang, S. Lu, D. Zhou, J. Dong and F. Liu

18 Systematic comparison of experimental and human obstructive cholestasis reveals conservation of canonical pathway activation and biomarkers relevant for cholestatic liver disease
E. Gijbels, K. De Muynck, B. Vanderborght, T. Meese, F. Van Nieuwerburgh, A. Vanlander, F. Berrevoet, B. Hendrikx, A. Hoorens, H. Van Vlierberghe, M. Vinken and L. Devisscher

22 Pivotal role of cytosolic phospholipase PLA2G4A in the pathogenesis of *FLT3*-ITD-mutated acute myeloid leukemia
W.-J. Lai, F. Chen, L. Shu, X.-M. Yang, J. Yuan, J.-B. Xu, A. Y.-H. Leung and B.-L. He

26 Identification of hsa_circ_0092576 regulatory network in the pathogenesis of coronary heart disease
A. Dandare, M. Rafiq, A. Liaquat, A. A. Raja and M. J. Khan

Contents continued on inside back cover

www.genesndiseases.org

ISSN 2352-4820

2352-3042(202301)10:1;1-M

9 772352 482230 01>

2023年1月出版
国内邮发代号：78-148
国内每册定价：￥40元

Contents continued from outside back cover

29 Irisin regulates pancreatic lipases through PPARγ-PGCα-FNDC5 pathway
H. Avital and B. Ruth

33 Lung adeno-squamous carcinoma modeling using oncogenic KRAS activation in human embryonic stem cell-derived alveolar organoids
J. Feng, L. Li, Z. Tan, S. Zhao, X. Zhang, J. Wang, Y. Ye, Y. Lin and Z. Rong

37 Simplifying genetic classifiers by six mutated genes in diffuse large B-cell lymphoma
J. Wang, F. Yu, W. Wei, J. Huang, Y. Shao, J. Yan, L. Mao, W. Yu, W. Xie and J. Jin

41 Prognostic value of the RNA editing enzyme: ADAR1, and its association with immune cells infiltration in pancreatic adenocarcinoma
J. Qi, Y. Zhou, Z. Zhu, C. Xu and W. Chen

45 Evidence that all Sorsby's fundus dystrophy mutations cause TIMP3 dimerization resulting in impaired inhibition of VEGFR2
F. A. Alsaffar, A. H. Mujamammi, M. S. K. Aldughaim, M. J. H. Nicklin and M. D. Barker

48 PD-L1 expression and smoke exposure as biomarkers for optimizing adjuvant therapy for patients with resected limited-stage small-cell lung carcinoma
C. Liu, Z. Wang, Q. Zeng, S. Zheng, X. Feng, Q. Xue, N. Sun and J. He

51 Androgen receptor inhibits the hair follicle induction potential of dermal papilla cells by binding with Tcf4 at the A574 binding site
N. Yu, T. Hu, H. Yang, L. Zhang, L. Zhu, X. Zhou, F. Xiang, X. Yang and Y. Li

55 Identification and validation of cardiac nonconserved human-specific enhancers
Y. Zhang, Y. Gui, X. Chen, F. Wang, F. Wu, Y. Wang, X. Wang, Y. Gui and Q. Li

58 KCNMA1 promotes obesity-related hypertension: Integrated analysis based on genome-wide association studies
Y. Zhou, Y. Zhao, L. Zha, M. Zhou, M. Wang, X. Cheng, Z. Huang, M. Liu, T. Ke and X. Tu

62 Integration of ATAC-Seq and RNA-Seq identifies the key genes in myocardial ischemia
J. Yuan, J.-M. Wang, Z.-W. Li, C.-S. Zhang, B. Cheng, S.-H. Yang, D.-J. Cai and S.-G. Yu

65 *SEMA4D* acts as a novel oligogenic pathogenic gene of idiopathic hypogonadotropic hypogonadism through the PlexinB1/MET/RND1/RHOA/RAF1/MAPK signaling axis
D. Wang, Y. Niu, J. Tan, J. Wang, L. Ling, Y. Chen, J. Gong, H. Xu, Q. Ling, J. Liu and J. Liu

Contents continued on BMV

Contents continued from inside back cover

69 Inhibition of ALDH2 by disulfiram leads to synthetic lethality via ROS strikes twice in *ARID1A*-deficient cholangiocarcinoma
T. Liang, L. Jia, R. Duan, L. Shen, D. Ren, Y. Ren, Y. Dou and L. Guo

72 Identification of Epsin1 as a regulator for hepatic lipid and glucose metabolism
X. Huang, L. Jin, Z. Fang, L. Che, Y. Lin, S. Xu, Y. Zhuo, M. Li, D. Wu and B. Feng

REVIEW ARTICLES

76 Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials
Y. Song, Z. Bi, Y. Liu, F. Qin, Y. Wei and X. Wei

89 The IL13α 2R paves the way for anti-glioma nanotherapy
I. V. Ulasov, A. Borovjagin, A. Laevskaya, M. Kamynina, P. Timashev, L. Cerchia and E. A. Rozhkova

101 PCK1 dysregulation in cancer: Metabolic reprogramming, oncogenic activation, and therapeutic opportunities
J. Xiang, K. Wang and N. Tang

113 Pathogenic roles of long noncoding RNAs in melanoma: Implications in diagnosis and therapies
Y. Xiao, Y. Xia, Y. Wang and C. Xue

126 N6-methyladenosine (m6A) modification of ribosomal RNAs (rRNAs): Critical roles in mRNA translation and diseases
K. Lei, S. Lin and Q. Yuan

135 Dynamic m6A-ncRNAs association and their impact on cancer pathogenesis, immune regulation and therapeutic response
Y. Yan, J. Peng, Q. Liang, X. Ren, Y. Cai, B. Peng, X. Chen, X. Wang, Q. Yi and Z. Xu

151 Inflammation and cancer: paradoxical roles in tumorigenesis and implications in immunotherapies
X. Liu, L. Yin, S. Shen and Y. Hou

165 mRNA alternative polyadenylation (APA) in regulation of gene expression and diseases
S. Guo and S. Lin

175 Adipose-derived stem cells and obesity: The spear and shield relationship
H. Yang, C. Li, Y. Li, R. Tai and C. Sun

187 SPINOPHILIN: A multiplayer tumor suppressor
E. M. Verdugo-Sivianes and A. Carnero

199 Drugging IGF-1R in cancer: New insights and emerging opportunities
P. Wang, V. C. Mak and L. W. Cheung

FULL LENGTH ARTICLES

212 Cell cycle dysregulation with overexpression of KIF2C/MCAK is a critical event in nasopharyngeal carcinoma
X. Zuo, P. Meng, Y. Bao, C. Tao, Y. Wang, X. Liu, Y. Bu and J. Zhu

228 Etiological roles of core promoter variation in triple-negative breast cancer
T. Huang, J. Li and S. M. Wang

239 *Desulfovibrio desulfuricans* aggravates atherosclerosis by enhancing intestinal permeability and endothelial TLR4/NF-κB pathway in *Apoe*−/− mice
K. Zhang, X. Qin, J. Qiu, T. Sun, K. Qu, A. U. Din, W. Yan, T. Li, Y. Chen, W. Gu, X. Rao and G. Wang

254 LOX upregulates FAK phosphorylation to promote metastasis in osteosarcoma
X. Chen, M. Clement, M. J. Hicks, P. Sarkar, M. W. Gaber and T.-K. Man

267 Inhibition of PRMT5 by market drugs as a novel cancer therapeutic avenue
L. Prabhu, M. Martin, L. Chen, Ö. Demir, J. Jin, X. Huang, A. Motolani, M. Sun, G. Jiang, H. Nakshatri, M. L. Fishel, S. Sun, A. Safa, R. E. Amaro, M. R. Kelley, Y. Liu, Z.-Y. Zhang and T. Lu

284 Liquiritigenin promotes osteogenic differentiation and prevents bone loss via inducing auto-lysosomal degradation and inhibiting apoptosis
Y. Qiu, Y. Zhao, Z. Long, A. Song, P. Huang, K. Wang, L. Xu, D. P. Molloy and G. He

Genes & Diseases

CONTENTS

Volume 10, Issue 1 **January 2023**

RESEARCH HIGHLIGHTS

1 Phase 'separating' 53BP1 from DSB repair
Y. Zhang

4 Metagenomic markings of myeloid malignancies
A. D. D. Nguyen, M. Shanteau-Jackson and T. LaFramboise

7 Does burning fat make tumor immune hot? Discovery of CD47 overexpression by radiation induced fatty acid oxidation
N. Jiang, B. Xie, M. Fan and J. J. Li

RNA polymerase II (Pol II) core promoter usually locates around the transcriptional start site with multiple highly conserved cis-elements. Core promoter sequences can be bound by Pol II and basal transcriptional factors (TFs) (i.e., TFIIA, TFIIB, TFIIC, TFIID, TFIIE and TFIIH), which form the pre-initiation complex (PIC) and then initiate the downstream genes expression. Abnormal gene expression plays a key role in cancer development. Huang et al reported the core promoter sequences are highly mutable in cancer. The mutated core promoter sequences can interfere with their interactions with transcriptional factors, resulting in altered transcriptional initiation and abnormal gene expression in triple-negative breast cancer (TNBC). Fortunately, some drugs targeting such core promoter variations have been found and may have potential clinical applications. As inspired by the legendary Chinese female fighter "Hua Mulan", who excelled in battlefields even more bravely than men. To protect her from being knocked over by an adversary (i.e., core promoter variation and abnormal gene expression in TNBC), precision targeting with spurred armors (i.e., targeted therapies of TNBC) is highly warranted (Illustration credit: Huijie Zhang, PhD, and Zijian Qu).

RAPID COMMUNICATIONS

10 Nuclear lncRNA CERNA1 enhances the cisplatin-induced cell apoptosis and overcomes chemoresistance via epigenetic activation of BCL2L10 in ovarian cancer
R. Xu, H. Peng, N. Yang, Z. Liu and W. Lu

14 PTGS2 identified as a biomarker of glucocorticoid-induced osteonecrosis of the femoral head and an enhancer of osteogenesis
Q. Zhang, S. Lu, D. Zhou, J. Dong and F. Liu

18 Systematic comparison of experimental and human obstructive cholestasis reveals conservation of canonical pathway activation and biomarkers relevant for cholestatic liver disease
E. Gijbels, K. De Muynck, B. Vanderborght, T. Meese, F. Van Nieuwerburgh, A. Vanlander, F. Berrevoet, B. Hendrikx, A. Hoorens, H. Van Vlierberghe, M. Vinken and L. Devisscher

22 Pivotal role of cytosolic phospholipase PLA2G4A in the pathogenesis of *FLT3*-ITD-mutated acute myeloid leukemia
W.-J. Lai, F. Chen, L. Shu, X.-M. Yang, J. Yuan, J.-B. Xu, A. Y.-H. Leung and B.-L. He

26 Identification of hsa_circ_0092576 regulatory network in the pathogenesis of coronary heart disease
A. Dandare, M. Rafiq, A. Liaquat, A. A. Raja and M. J. Khan

Contents continued on inside back cover

www.genesndiseases.org

ISSN 2352-4820

2352-3042(202301)10:1;1-M

9 772352 482230 01>

2023年1月出版
国内邮发代号：78-148
国内每册定价：￥40元